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Abstract: Granulatimide and isogranulatimide are alkaloids obtained from marine sources 
which have been shown to inhibit cell-cycle G2-checkpoint, targeting more particularly 
checkpoint 1 kinase (Chk1). At a structural level, they possess a characteristic 
pyrrolocarbazole framework also shared by the well-known rebeccamycin and 
staurosporine microbial metabolites which have been described to inhibit topoisomerase I 
and diverse kinases, respectively. This review reports precisely on the synthesis and kinase 
inhibitory activities of pyrrolocarbazole-based analogues of granulatimide.  
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1. Introduction  
 
Due to their key function in the phosphorylation of proteins, kinases act pivotally in signal 
transduction as well as in other cellular processes including metabolism, transcription, proliferation, 
apoptosis, differentiation and cell cycle progression [1]. With approximately 518 members encoded so 
far in the human genome, one thinks that at least one kinase is involved in every signal transduction 
pathway. As a result, kinases appear today as one of the most investigated classes of proteins for drug 
discovery.  
Small molecule kinase inhibitors have thus emerged both as promising molecules for use in cancer 
therapy and as experimental tools for understanding the physiological role of these enzymes [2–9]. In 
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this way, granulatimide and isogranulatimide, two naturally occurring alkaloids isolated from the 
marine ascidian Didemnum granulatum, were shown to be potent and selective inhibitors of Chk1 
(IC50 values are 0.25 and 0.1 μM, respectively), Chk1 being a key kinase of cell-cycle G2 checkpoint 
(Figure 1) [10,11]. 
 
Figure 1. Marine pyrrolocarbazoles and related natural compounds. 
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It is worth recalling here that the combination of a DNA damaging agent with a G2 checkpoint 
inhibitor constitutes a recent and attractive chemotherapeutic approach for cancer treatment. Indeed, 
cells respond to DNA damage by activating feedback mechanisms called checkpoints that temporarily 
delays the cell cycle progression and allows for DNA repair [12]. DNA damage triggers ATM and 
ATR protein kinases which activate Chk1 and Chk2. These checkpoint kinases, in turn, inactivate 
CDC25 and prevent Cdc2 activation resulting in cell cycle arrest [13]. A majority of human cancers 
completely lack a G1 checkpoint because of mutation of the p53 tumor suppressor gene and many 
cancer cells have a partially defective G2 checkpoint. Accordingly, combination of a DNA damaging 
agent with a G2 checkpoint inhibitor might promote cell death, by selective killing of p53-mutated 
tumor cells. 
From a structural point of view, granulatimide and isogranulatimide possess a pyrrolocarbazole 
framework (i.e., heterocyclic system composed of units A, B, C and D) bearing a fused imidazole 
heterocycle (unit E, Figure 1). Other structurally related pyrrolocarbazoles, such as staurosporine or 
UCN-01, were also shown to be potent but non selective inhibitors of Chk1. In terms of kinase 
specificity, it is noteworthy that granulatimide and isogranulatimide also inhibit Cdk1 and GSK-3β, 
but show less potent inhibitory activity on several other protein kinases [14]. During the last decade, 
large structure-activity relationship studies were carried out on these compounds, which led to more Mar. Drugs 2009, 7 
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potent and more selective molecules. Whereas a previous account by Hénon et al. was devoted to 
pyrrolocarbazoles as Chk1 inhibitors [15], the present review will update and enlarge this topic, 
focusing on synthesis and kinase inhibition profile of analogues of the marine metabolites. 
 
2. Marine-Related Metabolites and Positional Analogues 
 
Granulatimide and isogranulatimide were first described together with didemnimide E from the 
ascidian Didemnum granulatum [10,16] (Figure 1). Isogranulatimide was also found in the Caribbean 
ascidian Didemnum conchyliatum [17] from which didemnimides A-D were isolated before [18]. Later 
on, reinvestigation of the extracts allowed the isolation of a new related alkaloid, i.e.,  
6-bromogranulatimide [19]. More recently, Seleghim et al.  have addressed the question of the 
biosynthetic source of the two metabolites granulatimide and isogranulatimide by localizing them 
within the ascidian. They demonstrated that granulatimide is stored in Didemnum granulatum tunic 
bladder cells [20]. 
Since granulatimide and isogranulatimide have been shown to be abrogators of the cell-cycle G2-M 
phase checkpoint, two efficient synthetic routes have been developed for these compounds   
(Scheme 1). The first one by Piers et al. proceeded via their putative biosynthetic precursor 
didemnimide A and was based on the condensation of the substituted imidazole 1 with indole-3-
acetamide (route A) [21]. The other one proposed by Yoshida et al. relied on a key Stille coupling 
reaction between stannylindole 2 and 4-iodoimidazole in the presence of PdCl2(PPh)3 [22] (route B). 
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The synthesis of positional analogues of granulatimide and isogranulatimide were also reported, 
mainly modified at the level of the imidazole ring. The first derivatives were synthesized by Piers et al. Mar. Drugs 2009, 7 
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who prepared isogranulatimide A-C and 17-methyl granulatimide 3 by using the synthetic route they 
defined for the natural product [21] (Figure 2). Among them, the most interesting compounds 
isogranulatimide B and isogranulatimide C inhibited the G2 checkpoint with IC50 values of 1 and  
6 μM, respectively and Chk1 with IC50 of 2.3 and 0.65 μM respectively.  
 
Figure 2. Marine-related metabolites and positional analogues of granulatimide. 
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Compound 3 was also published by Yoshida et al. together with 10-methylgranulatimide 4 and the 
disubstituted 10,17-dimethylgranulatimide 5  [22]. One year later, the same group proposed the 
positional isomers of the two last ones (6 and 7 respectively) [23]. 10-methyl isogranulatimide (8) 
which was proven about 15-fold less potent than granulatimide on the G2 checkpoint assay and the  
9-hydroxylated analog 9, which did not exhibit a significant activity were also prepared [13]. 
 
3. Modification of the Indole Subunit (Units A and B) 
 
The main modifications of the indole moiety consisted of: (i) introduction of substituents, (ii) 
replacement of this cycle by an azaindole unit, (iii) introduction of a glycosyl moiety attached to the 
indole nitrogen [15]. All of these compounds were proved to be poor Chk1 inhibitors, the presence of a 
methyl group on the imide nitrogen may be contributing to this negative result [24]. 
 
4. Replacement of the Imidazole Ring (Unit E)  
 
4.1. By a pyrrole or by a second maleimide moiety 
 
Most of the analogues of granulatimide and isogranulatimide reported so far result from 
replacement of the imidazole heterocycle by other heterocycles. Among them, both pyrrole derivatives Mar. Drugs 2009, 7 
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and compounds in which the imidazole ring was replaced by a second maleimide moiety were 
investigated. As these compounds were intensively recapitulated in Hénon’s review [15], we just 
report here those which gave the most interesting results regarding their inhibitory activity toward 
Chk1 and their in vitro cytotoxicities toward four tumor cell lines including L1210, DU145, A549 and 
HT29 (Figure 3).  
 
Figure 3. Granulatimide analogues with a pyrrole or a second maleimide moiety replacing 
the imidazole ring. 
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In the pyrrole series, compounds 10  to 13  exhibit stronger Chk1 inhibitory activities than 
granulatimide and isogranulatimide. Moreover, compounds 11 and 12 showed a significant selectivity 
for Chk1 when evaluated toward a large panel of kinases. There was no correlation between Chk1 
inhibitory activities and cytotoxicities, the compounds exhibiting cytotoxicities in the same range than 
isogranulatimide. It was also proven in this study that in contrast with UCN-01, the new compounds 
did not bind to DNA [25]. 
In the second series, compound 14 and 15 exhibited IC50 values of 2 and 8 nM, respectively which 
makes them more potent Chk1 inhibitors than the natural products. The cytotoxicities toward the 
tumor cell lines tested including L1210, DU145, A549, HCT116 and HT29 were moderate in the case 
of all studied compounds except for compounds 15, 16 and 17 [26]. 
 
4.2. By a non aromatic five or six-membered-ring moiety 
 
A series of pyrrolocarbazoles 18–26 in which the imidazole heterocycle has been replaced by a 
five- or a six-membered ring carbocycle bearing one or two carbonyl functions have been published by 
Conchon et al. [27,28]. The compounds of the series were obtained either on the basis of a Suzuki 
coupling between 2-N-Boc-indoleboronic acid and 3-bromocyclopent-2-enone or 4-bromo-2,2-
dimethylcyclopent-4-ene-1,3-dione followed by a Diels-Alder reaction of the adducts with maleimide 
(Scheme 2) or via a Diels-Alder reaction between 3-indolylmaleimide or 5-substituted-3-
indolylmaleimide and different dienophiles such as cyclopent-2-enone, cyclohex-2-enone, 
hydroquinone, 2,2-dimethylcyclopentenedione and ethyl cis-β-cyanoacrylate (Scheme 3).  
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Among the most potent Chk1 inhibitors in this group, quinone 24 and compound 26 with a lactam 
D ring, exhibited IC50 values of 27 and 24 nM, respectively. This study showed that the D-heterocycle 
can be replaced by a carbocycle without loss of Chk1 activity. In addition, no parallel was observed 
between the cytotoxicities and the Chk1 inhibitory activities. Mar. Drugs 2009, 7 
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Another pyrrolocarbazole series including compounds 29–53  related to granulatimide was 
identified as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. This enzyme is a nuclear 
enzyme that catalyzes the synthesis of poly(ADP-ribose) chains from NAD
+ in response to single-
strand DNA breaks as part of the DNA repair process [29,30]. The synthesis of compounds is shown in 
Scheme 4.  
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The key diene 27 was prepared by sequential deprotonation of indole with n-BuLi, followed by 
treatment with carbon dioxide. Removal of excess CO2 and treatment with t-BuLi and cyclopentanone 
gave the tertiary alcohol which was dehydrated with hydrochloric acid to give 27. Diels-Alder reaction 
of  27 with maleimide followed by DDQ oxidation gave the pyrrolocarbazole 29 whereas the 
interaction of 27 with cis-ethyl-3 cyanoacrylate in chlorobenzene led to a mixture of two nitrile-ester 
regioisomers which were separated. Subsequent DDQ oxidation of the so-obtained cycloadducts gave 
the corresponding derivatives 30 and 31. Reduction of the nitrile function and spontaneous cyclization 
gave lactams 32 and 33, respectively. Compound 33 was then submitted to diverse reaction conditions 
to give various analogues 34–52. It is worth noting that the analog 53, which did not feature the 
pyrrolocarbazole skeleton, was obtained by using a similar sequence of reactions. All the compounds Mar. Drugs 2009, 7 
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prepared in this study were evaluated as inhibitors of recombinant human PARP-1. The results for 
compounds 29–53 reported in Table 1 are not exhaustive.  
 
Table 1. PARP in vitro activity of pyrrolocarbazole. 
N
H
H
N O O
29
N
H
H
N O O
53
N
N O
33-52
A
R
B
 
Compound A  B  R  PARP-1 IC50 (nM)
29  - -    36 
33  H H  H  56 
34  H H  Cl  120 
35  H H  Br  30 
36  H H  CN  18 
37  H H  CH2NH2 27 
38  H H  Me  200 
39  H H  CO2H 80 
40  H H  CO2Me 59 
41  H H  CONH-(CH2)2-NMe2 165 
42  H H  CONH-(CH2)2-morpholin-4-yl 162 
43  H H  CO-morpholin-4-yl  83 
44  H H  CON(Me)-CH2-pyrid-4-yl 65 
45  H H  CON(Me)-CH2-pyrid-2-yl 237 
46  H H  CON(Me)-(CH2)2-imidazol-4-yl 161 
47  H H  CONH-(CH2)2-triazol-1-yl 105 
48  H H  CH2NHCOCH-(NHBoc)[(CH2)4NHBoc] 670 
49  H H  CH2NHCOCH-(NH2)[(CH2)4NH2] 80 
50  H Me  H  800 
51  Me Me  H  10,000 
52  CHO H H  3,000 
53  - -    40 
 
For example, different structures comprising different moieties instead of the cyclopentyl cycle E 
were also studied but they did not exhibit any inhibitory activity against the enzyme suggesting that 
this cycle is required for potency and fits into a catalytically active steric pocket of the enzyme. Data in 
Table 1 show an essential H-bonding interaction of both indole and lactam NH-groups within the 
active site of the enzyme. An open pocket near the active site corresponding to the 3 and 4 positions of 
the carbazole template allowed development of a SAR around this region, nevertheless this B ring is 
not required for activity.   Mar. Drugs 2009, 7 
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4.3. By another aryl or heteroaryl ring moiety 
 
Different analogues of granulatimide modified at the imidazole unit by an other aryl or heteroaryl 
ring have been proposed. In order to define new Cyclin D1-CDK4 inhibitors, Lilly Research 
Laboratories investigated a first series of analogues 54–64 [31] (Scheme 5).  
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Figure 4. Granulatimide analogues with different aromatic moieties instead of the imidazole ring. 
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Cyclin-CDK complexes regulate the progression of cells through the cell cycle, a G1-phase role 
being suggested for D-type cyclins through association with CDK4 and CDK6. Since abberations in 
CDKs and their regulators have been found in a large percentage of human tumors, inhibitors of these 
cyclin-CDK complexes might have a broad range of therapeutic applications in cancer. The 
preparation of the compounds was accomplished following Faul’s general synthetic route to access the 
3-heteroaryl-4-indolyl maleimides which were cyclized either by using APTS as catalyst or by 
oxidative photochemistry [32,33]. Their inhibitory activity against cyclin D1-CDK4 was evaluated. 
From all the compounds, the naphtyl[2,1-a] derivative 54 was proven to be a potent and selective 
inhibitor (IC50 = 45 nM). 
From a second series 65–79, in which the [3,4-c]carbazole core was fused with a quinolyl or 
isoquinolyl moiety, compound 68 was found to be the highest potent D1-CDK4 inhibitor with an IC50 
of 69 nM (Figure 4). This last compound inhibited tumor cell growth, arrested tumor cells in G1-phase 
and inhibited pRb phosphorylation [34]. In 2005, Routier et al. were interested in pyrrolocarbazole-
fused naphthalenes and reported an efficient route to these family of compounds 81 involving 
palladium-catalyzed reactions to prepare them (Scheme 6) [35]. 
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The introduction of a 2-hydroxynaphthyl group on 2-bromo-3-indolomaleimide was performed 
using a Suzuki or Stille coupling reaction with adequate palladium catalysts. The activation of the 
naphthyl as a naphthyl triflate was realized before the central six-membered ring was obtained through 
an elegant intramolecular Heck reaction. Different related compounds were prepared either by 
functionalizing the free indolic nitrogen of 80, or by performing substitutions on the maleimide group. 
Some of these molecules showed marked cytotoxicity toward cancer cells including L1210, DU145 Mar. Drugs 2009, 7 
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and HT29 with IC50 values in the sub-micromolar range. DNA binding likely contributes to the 
antiproliferative activity of the most cytotoxic compounds. However, no kinase inhibition was detected 
in this group of compounds. A second series 82–89 in which the imidazole ring was replaced by a 
phenyl group and including indolic substitution and maleimide variations was proposed by the same 
group [36] (Figure 5).  
 
Figure 5. Phenylpyrrolocarbazoles proposed by Routier et al.  
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The compounds were prepared according to the previously described synthetic scheme, the final 
intramolecular key Heck-type reaction being carried out with either a triflate or a brominated 
derivative. Several compounds showed a marked cytotoxicity against CEM human leukemia cells with 
IC50 values in the 10–100 nM range. Although cell cycle analysis, topoisomerase I inhibition, 
interaction with DNA and inhibition of CDK activity were evaluated, the exact molecular targets of 
these molecules remain undiscovered. In their work to define new checkpoint kinase inhibitors, 
Conchon et al. were also interested in dihydroxy-phenylcarbazoles 90–92 which were prepared by 
reduction of the corresponding quinonic compounds 22–24 [27] (Figure 6).  
 
Figure 6. Dihydroxyphenylcarbazoles. 
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These derivatives were shown to be potent inhibitors of the enzyme (IC50 0.311, 0.161 and   
0.023 μM, respectively) exhibiting Chk1 inhibitory properties very close to their analogues 22–24.  In 
2004, during the course of their studies for developing ruthenium complexes that target the ATP-
binding site of protein kinases, Meggers and his co-workers were interested in a granulatimide 
analogue  93 in which the imidazole ring has been replaced by a pyridinic ring (Figure 7). This 
cyclopentadienyl half sandwich ruthenium complex was tested as a racemic mixture against a panel of 
protein kinases and was thus identified as an extremely potent inhibitor for GSK-3 (IC50 of 3 nM for 
GSK-3α and 10 nM for GSK-3β), being 15,000 times more active than the ligand itself [37]. It is 
worth precising here that GSK-3 (glycogen synthase kinase-3) has been shown to be a key component 
of a diverse range of cellular processes including the regulation of glycogen metabolism or signal 
transduction in the insulin and wnt signal pathways [38]. 
 
Figure 7. Pyridopyrrolocarbazole half-sandwich ruthenium complex. 
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They also reported another ruthenium complex 94 which is a highly potent inhibitor for the enzyme 
and demonstrated that this compound can switch on the wnt signal transduction pathway inside living 
cells and in Xenopus embryos (wnt is a secreted glycoprotein which initiates the phosphorylation of  
β-catenin) [39]. Later on, they performed two synthetically routes to pyrrolocarbazole-fused pyridines 
including either an oxidative or nonoxidative photocyclisation step, the second one being specially 
useful for the preparation of such analogs [40] (Scheme 7). 
In an attempt to improve the selectivity profile for GSK-3, this group achieved a simple structure-
activity relationship study, starting by modifying the indole moiety and the cyclopentadienyl ligand of 
the half sandwich scaffold 93. The synthesis of one compound is shown in Scheme 8.  
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Synthon 99, obtained by regioselective bromination of the pyridocarbazole ligand 98 was reacted in 
presence of K2CO3 with cyclopentadienyl derivative 97, itself prepared in two steps from 
(methylcarbonyl)cyclopentadienyl sodium 95. Removal of the TBS group of the adduct yielded 
ruthenium complex 100. After resolution of the racemic mixture, compound (R)-100 was identified as 
the most selective derivative of GSK-3 (IC50 of 0.35 nM for GSK-3α and 0.55 nM for   
GSK-3β) against a panel of 57 protein kinases [41].  
An efficient method involving an organoruthenium compound bearing a N-succinimidyl ester at the 
cyclopentadienyl moiety was then developed for the rapid modification of the cyclopentadienyl moiety 
of ruthenium half sandwich protein kinase inhibitors. The quenching of this activated ester with 
different amines led to the identification of Pim-1 and GSK-3 inhibitors with improved potencies and 
selectivities, respectively, compounds 101 and 102 [42] (Scheme 9). 
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Scheme 9.  
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A strategy that allows a rapid scanning of ligands around the ruthenium center in the search for 
ligand spheres that are complementary in shape and functional group presentation to ATP binding sites 
of individual protein kinases was presented [43]. Following this approach, octahedral ruthenium 
complexes 104–106, prepared from precursor 103 were identified as potent inhibitors for the protein 
kinases Pim-1, MSK-1 and GSK-3α (Scheme 10). 
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In 2008, Meggers’s group reported compound (RRu) 107 containing a fluorine substituent on the 
pyridinic ring, to be an extremely high-affinity GSK-3 inhibitor (IC50 < 0.04 nM) (Figure 8) [44]. This 
compound was proven to perfectly complement the shape of the ATP-binding site making it one of the 
most potent protein kinase inhibitors reported to date. 
More recently, the organoruthenium complex 108 in which the pyridinic ring has been replaced by 
an isoquinolic ring was proposed by Anand et al. to be a potent and selective Mammalian Sterile 20 
kinase (MST-20) inhibitor [45]. This enzyme is a proapoptotic cytosolic kinase that plays an important 
role in diverse biological processes including the cellular response to oxidative stress.  
 
Figure 8. Fluoropyrido- and isoquinolino-pyrrolocarbazole half-sandwich ruthenium complex. 
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4.4. By a second indole ring 
 
Granulatimide analogues in which the imidazole moiety is replaced by a second indole ring are 
compounds also structurally very close to rebeccamycin and staurosporine antibiotics. These two 
compounds, isolated, respectively, from cultures of Saccharotrix aerocologines [46] and Streptomyces 
[47,48] differ by the sugar linked to only one indole nitrogen in rebeccamycin which contains also an 
imide function instead of amide function in the upper heterocycle. From a biological point of view, 
these disparities seem crucial in the sense that the target of these microbial metabolites are quite 
different. Rebeccamycin has been demonstrated to inhibit topoisomerase I, by stabilizing the enzyme-
DNA interaction via a “cleavable complex”, but appeared to be inactive against PKC and PKA [49]; 
on the contrary, staurosporine is a non selective kinase inhibitor without activity against 
topoisomerases [50–53]. Large structure-activity relationship studies were carried out on these 
pyrrolocarbazole-fused indoles which were previously reviewed [54,55]. In the following, only works 
realized since 2003, will be treated. 
New rebeccamycin-related metabolites issued from natural source have been described including  
6-hydroxystaurosporine 109 and 5,6-dihydroxyarcyriaflavin A 110 which were isolated from field-
collected fruit bodies of a myxomycetes Lycogala epidendrum [56] (Figure 9).  
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Figure 9. New natural indolocarbazole analogues. 
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These compounds showed interesting cytotoxicity against HeLa, Jurkat, and vincristine resistant 
KB/VJ300 cells, compound 109 also inhibiting protein tyrosine kinase activity. In continuation of their 
work devoted to the design of potent and selective cyclin D1/CDK4 inhibitors, workers at Lilly 
Research Laboratories investigated a series of [6,7-a]pyrrolo[3,4-c]carbazoles 111 substituted on the 
indolic nitrogens or on the indolic rings as well as other series 112–115 bearing different groups at 
N13 and C12 positions to improve aqueous solubility [57] (Figure 10). These compounds were 
prepared according to Faul’s synthetic scheme requiring new methods to access to   
7-substituted indole acetamides and N-methyl(indol-7-yl)oxoacetates [58].  
 
Figure 10. Indolo[6,7-a] pyrrolo[3,4-c]carbazoles. 
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In addition to their potent CDK activity, the compounds displayed antiproliferative activity against 
two human cancer cell lines, i.e., HCT-116 and H460. These inhibitors also effected strong G1-arrest 
in these cell lines and inhibited Rb phosphorylation consistent with inhibition of cyclin D1-CDK4. In 
continuous effort to optimize pharmacokinetic properties of these inhibitors, the pharmaceutic group Mar. Drugs 2009, 7 
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went on exploring four series 116–119 of novel analogues by introducing a 1,7-annulated ring in one 
of the indole moiety [59,60] (Figure 11).  
 
Figure 11. 1,7-Annulated indolocarbazoles. 
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The compounds were obtained by submitting different 1,7-annulated indolyl-3-glyoxylates to 
Faul’s procedure. They all exhibited potent inhibitory activity against cyclin D1-CDK4 and good 
antiproliferative activity against HCT-116.  
In the course of structure-activity relationship studies, Prudhomme and co-workers prepared by 
semi-synthesis from rebeccamycin, new indolocarbazole analogues 120–126 substituted in 3,9-
positions on the indolecarbazole framework along with the 2’,3’-epoxyderivative 127 (Figure 12) [61].  
 
Figure 12. Indolocarbazole analogues substituted in 3,9-positions and 2’,3’-epoxyderivative 127. 
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The antiproliferative activities were assayed for these compounds against nine tumor cell lines and 
the effects on the cell cycle of murine leukaemia L1210 cells was examined. Their topoisomerase I 
inhibitory activity both with their activity toward three kinases including PKCζ, CDK1/cyclin B and Mar. Drugs 2009, 7 
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CDK5/p25 were also evaluated. Among the different compounds of these series, the diphenol 125 was 
the most efficient toward CDK1/cyclin B and CDK5/p25 and appeared also to be a DNA-binder and a 
topoisomerase I poison. All these activities likely accounted for its cytotoxic potential. 
Another series of rebeccamycin analogues 128–145 fluoro-substituted in the same 3,9 and/or   
2,10-positions of the carbazole core was studied by Balasubramanian et al.  with respect to their 
topoisomerase I activity, cytotoxicity, selectivity and in vivo antitumor activity [62] (Table 2).  
 
Table 2.  Structure-in vitro  activity relationships for some indolocarbazole analogues 
against human topoisomerase I and murine P388 leukemia cells. 
NX
N OO
O OH
OH
HO
HO
R
2
3 9
10
6'
6
        
NN
H
H
N OO
O OH
OH
F
HO
135
F F
 
Compound   X  R  Topo
a P388
b R/S
c 
 rebeccamycin  NH  H  >500  0.54  1.26 
128  2,10-diF NH  H  2.0  0.26  8.7 
129  3,9-diF NH  H  0.22  0.018  182.7 
130  2,3,9,10-tetraF NH  H  0.69  0.007  67.1 
131  2,3,9,10-tetraF NMe2 H  >600  >8.72  >1.1 
132  3-F NH  H  6.6  1.036  >905 
133  2-F NH  H  3.1  0.392  4.6 
134  10-F NH  H  >200  0.098  11.4 
135
d  9-F NH  H  1.7  0.101  31.7 
136  3-F S  H  2.2  0.155  >51.3 
137  3,9-diF S  H  0.09  0.010  232.5 
138  3-F O  H  1.5  0.529  13.6 
139  3,9-diF O  H  0.27  0.114  63.7 
140  3,9-diF NH  NH2 0.22  0.020  196.9 
141  3,9-diF NH  OH  0.08  0.035  19.6 
142  3,9-diF NH  Me  1.0  0.862  >10.8 
143  3,9-diF S  Me  0.48  0.236  14.1 
144
e  3,9-diF NH  H  0.28  0.326  28 
145
e  3,9-diF S  H  0.46  0.068  >115 
146  3,9-diF NH  H  0.11  0.002  380 
a Ratio of the median effective concentration (EC50, μM) of compounds for inducing single-strand breaks in 
the DNA substrate divided by that obtained for CPT in the same experiment. CPT mean topo I   
EC50 = 160 nM.
b Mean cytotoxic concentration (IC50, μM) following 3 days of continuous exposure of 
compound to P388 murine leukaemia cells. CPT mean P388 IC50 = 36 nM. 
c Ratio resulting from the 
cytotoxicity IC50 value obtained for CPT-resistant P388/CPT45 cells divided by that obtained for parental 
P388 cells. 
d Inseparable mixture with 132. 
e Both 144 and 145 are 6’-NH2 analogues. 
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The different fluorinated cores were obtained either via a stepwise addition of an appropriately 
substituted indole-based Grignard reagent (e.g., 128–135, 140–142) to a dihalomaleimide followed by 
oxidative cyclization or by using the Fischer indole process as an attractive alternative for the 
preparation of both benzofurane- and benzothiophene-fused pyrrolocarbazole analogs 136–139 and 
143 (Scheme 11).  
Scheme 11.  
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The introduction of the sugar moiety was finally realized using well established glycosylation 
procedures. Two additional compounds 144 and 145 being 6’-NH2 analogues of 129 and 137 
respectively, were also prepared in order to solve solubility problems. Emerging from this series as a 
potential clinical candidate was compound 145 which exhibited in vitro topoisomerase I mediated 
cleavage activity and topoisomerase I selective cytotoxic profile with improved solubility and 
pharmacokinetic behaviour. In continuation of this work and considering that the introduction of a  
3,9-difluoro substitution pattern on the indolocarbazole core confers topo I selectivity, the same group 
proposed a new series of analogues similarly fluorosubstituted in the carbazole framework but also 
fluoroglycosylated [63]. The introduction of fluorine into the 2’, 4’ and 6’ positions of the sugar 
portion of the molecule was accomplished both pre- and post-glycosylation. From this series, 
compound 146 displayed a broad spectrum antitumor activity (superior to CPT-11!) against some 
preclinical xenograft models, including curative antitumor activity against Lewis lung carcinoma, and 
was consequently chosen as a lead clinical candidate (Table 2). Mar. Drugs 2009, 7 
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Since the sugar moiety is often the critical determinant of the key biological activity of indolo[2,3-
a]carbazoles, inhibition of protein kinases for compounds containing two glycosidic bonds (e.g., 
staurosporine) or DNA-binding and antitumor properties for compounds with only one glycosidic 
linkage (e.g., rebeccamycin), this element of structure has been extensively investigated. In 2003, 
Anizon et al. reported a chlorinated (147–151, 160) and a dechlorinated (152–159, 161) series of 
rebeccamycin analogues bearing diverse substituents on the sugar moiety [64] (Figure 13). 
 
Figure 13. Rebeccamycin analogues bearing different substituents on the sugar moiety. 
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Their interaction with DNA and their effects on human DNA topoisomerases I and II were studied. 
The incorporation of a 6’-amino group reinforces the capacity of the drugs to interact with DNA but 
almost abolishes their poisoning effect on topoisomerase I suggesting that DNA and topoisomerase I 
represent two independent targets. 
Another series of pyrrolocarbazole-fused indole analogues that lack the aryl chlorine group and in 
which the 4-O-methylglucose moiety has been replaced by a naturally occurring sugar including   
D-glucose (165a),  D-galactose (165b),  L-fucose (165c),  L-rhamnose (165d),  D-xylose (165e) and   
D-maltose (165f) was described by Faul et al. [65]. These compounds were prepared according to an 
efficient two-step process via the indole-indoline intermediate 163 which was obtained by performing 
at 0 °C an intramolecular Mannich process starting from precursor 162. Compound 163 was 
glycosylated and the resulting products were oxidized in a one-pot procedure (Scheme 12). Mar. Drugs 2009, 7 
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Scheme 12.  
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Compounds 165a–f  were evaluated for their D1-CDK4 inhibitory activity. In addition, other assays 
such as B-CDK1, E-CDK2, PKA and CAM II were also conducted to determine their selectivity 
profile. All the compounds demonstrated good inhibitory activity for D1-CDK4 and they also showed 
improved selectivity toward several other kinases, the L-rhamnose derivative 165d being found to be 
the most selective and potent analogue for D1-CDK4 (IC50 = 76 nM). More recently, Zhang and co-
workers investigated rebeccamycin analogues containing uncommon sugars [66]. They proposed four 
groups of compounds 167–177 depending on the substituent on the imide nitrogen (Figure 14).  
 
Figure 14. Rebeccamycin analogues with uncommon sugar. 
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Their cytotoxicities against colon cancer and leukaemia cells together with their ability to target 
topoisomerase I were examined. Compared with the aglycon 166, the modified compounds showed 
more potent cytotoxicities and topoisomerase I targeting ability. The better activities of compounds 
167, 173, 169 and 174 imply that the 2- and 6-OH groups may have a more significant role than other 
OH groups in the sugar unit. In addition, the cytotoxicities of these compounds clearly correlated with 
the inhibition of topo I suggesting that the sugar moiety, especially the 2- and 6-positions, is a key 
element for the activity. 
During their work to identify novel potential inhibitors of Chk1 related to the indolocarbazoles 178 
and 179 [67], Gribble et al. have synthesized and tested two new nitrile homologues 180 and 181 and 
an amide analogue 182  [68] (Figure 15). This series of compounds can be considered both as 
granulatimide analogues in which the imidazole ring has been replaced by a second indole ring or as 
rebeccamycin analogues in which the sugar part was replaced by a functional chain.  
 
Figure 15. Rebeccamycin analogues substituted on the indole nitrogens. 
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All the compounds were obtained by adapting the methodology previously described by Faul et al. 
[69,70] in which the construction of the bisindolyl maleimide was realized by condensation of indole-
3-acetamide with methyl indole-3-glyoxylate (Scheme 13). 
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In the case of compound 182, the amide-chain was attached on the indole-3-acetic acid fragment in 
order to circumvent solubility problems. In an assay using flow cytometry analysis, compounds 180, 
181 and 182 were found less potent (3 μM, 10 μM and 1–3 μM respectively) than compound 179  
(100 nM) at abrogating DNA damage-induced cell cycle arrest. These values were compared to the 
efficiency of 178 of 30 nM in the same assay. From these results, it was found that a three-carbon 
nitrile chain provided maximum activity and that the cyano group was a more desirable functionality 
than the amide. 
In the course of their structure-activity relationship studies, by using the same methodology, the 
same group then prepared the two hydrochloride compounds 183 and 184, as other amine-analogues 
[71]. Compound 184 was proved to abrogate S-phase arrest at 100 nM indicating that it inhibits Chk1 
whereas compound 183 was found inactive in the same flow cytometry assay. 
One of the modifications in rebeccamycin structure previously described by Routier and cols.  
[72,73], but since extensively studied by Prudhomme and her group, is the bioisosteric replacement of 
an indole moiety by a 7-azaindole unit [74]. They have first been interested in a series of compounds 
185–191 containing one azaindole unit with or without a methyl group on the imide nitrogen and with 
the sugar moiety linked either to the indole nitrogen or to the azaindole nitrogen (Figure 16).  
 
Figure 16.  7-Azarebeccamycin analogues bearing one or two azaindole moieties and 
dechlorinated rebeccamycin analogues B and C. 
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In a second series of analogues 192–193, the two indole moieties of rebeccamycin were replaced by 
two aza-indole units (Figure 16). The compounds were synthesized according to strategies already 
described. Depending on the expected product, the sugar part was introduced before or after the 
cyclization which formed the central benzenic ring (i.e., unit C). In the case of post-glycosylation 
approach, the substitution of the 9-indole hydrogen was realized in the last step. The DNA-binding and 
topoisomerase I inhibition properties of the new compounds were investigated together with the 
antiproliferative activities toward nine tumor cell lines and their effects on the cell cycle of L1210 
leukemia cells. In contrast to their non-azaanalogues (rebeccamycin, dechlorinated rebeccamycin B 
and compound C), which were cytotoxic for all the cell lines tested, the azaanalogues showed a 
selective action toward certain cell lines in the nanomolar range. All compounds induced similar cell 
cycle effects, with a marked G2+M block observed with L1210 leukemia cells. In addition, the sugar 
unit linked to the indole moiety promoted higher affinity for DNA whereas compounds with the sugar 
linked to the azaindole moiety have lost their DNA-binding affinity. In these series, a good correlation 
between DNA binding and topoisomerase I inhibition was observed. These data suggest the possibility 
of targets other than DNA and topoisomerase I for the azaanalogues.  
The next step in the investigation of 7-azarebeccamycin related compounds was the study of 
bridged azaanalogues, namely compounds with both indole and azaindole moieties linked to the 
carbohydrate residue (Scheme 14).  
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A previous report described the preparation of compound 194 which could be achieved by coupling 
a chloro sugar moiety previously tosylated in 2’-position to the corresponding azaindolocarbazole 
aglycone and subsequent reaction with sodium azide in DMF [75] (Figure 17). A series of compounds 
195–197 bearing a free imide nitrogen and in which the oxygen of the pyranose heterocycle is oriented 
toward either the indole or the azaindole unit was then proposed [76]. The same methodology was Mar. Drugs 2009, 7 
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applied to synthesize the derivative 196 using a 2’-tosylated instead of a 2’-chloro glycosyl donor. No 
data on cytotoxicity and inhibitory activities of these compounds towards various kinases are available 
so far.  
 
Figure 17. Bridged aza-rebeccamycin analogues. 
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In the next proposed series, the modifications have been carried out together on the upper 
heterocycle (introduction of substituents on the imide nitrogen or replacement of the imide by a lactam 
function), on the carbazole framework and the sugar part, this last unit being linked either to the 
azaindole moiety (198–202) or to the indole (203–208) [77] (Figure 18). 
 
Figure 18. 7-Aza-rebeccamycin analogues with various substituents on the sugar moiety, 
on the imide nitrogen, on the carbazole framework or on the nitrogen of the pyridine ring. 
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The cytotoxicities of these compounds toward four tumor cell lines including L1210, A549, DU145 
and HT29 showed that compared with the parent compounds, the modifications on the new analogues 
are not detrimental to the in vitro activities. As shown in the case of previous series, when the sugar 
part was linked to the indole moiety, the affinity for DNA and topoisomerase I inhibition were highly 
enhanced compared with non-aza parent compounds whereas, when the sugar was attached to the 
azaindole, the affinity for DNA and topoisomerase I inhibition were highly decreased. Nevertheless, 
strong cytotoxicities were observed toward certain cell lines, probably due to other targets. 
In the last series of azaanalogues examined by Prudhomme’s group 209–211, the sugar moiety was 
linked to the nitrogen of the pyridine ring [78] (Figure 18). These products were obtained as by-
products in the course of the synthesis of 7-azaanalogues, precisely during the final Mitsunobu-type 
glycosylation step. The binding to DNA appeared enhanced in the case of these new compounds. 
However, as observed with other rebeccamycin analogues, the DNA-binding affinity was not 
correlated with topoisomerase I inhibitory properties. It seemed also, from a Chk1 inhibitory point of 
view which was also examined in this series, that the shifting of the sugar from the nitrogen of the 
indole to the nitrogen of the pyridine increased the effect. 
 
5. Granulatimide Analogues in Which the D and E Rings Are Modified or Absent 
 
In the course of structure-activity relationship studies on granulatimide as Chk1 inhibitors, 
substituted pyrrolocarbazoles 212–215 in which the upper imide-type unit D is missing and 
pyrrolocarbazoles  216  and 217 , in which the imidazole unit E is missing were investigated [79]   
(Figure 19).  
 
Figure 19. Granulatimide analogues in which the D and E rings are modified or absent. 
N
H
CO2Et
X OO
N
H
R2 R1
NR3
O
O
212 R1 = OH, R2 = CO2Et, R3 = BOM
213 R1 = OH, R2 = R3 = H
214 R1 = OH, R2 = CO2Et, R3 = CH2OH
215 R1 = OH, R2 = CO2Et, R3 = H
216 X = NH
217 X = NCH2OH
E
D
 
 
The compounds of the first series were synthesized via compound 212 itself obtained by reaction of 
ethyl-3-oxo-(1H-indol-3-yl)propionate and N-BOM-dibromomaleimide whereas the derivatives of the 
second series were prepared on the basis of a Diels-Alder reaction between indolylmaleimide and ethyl 
acrylate. Concerning biological activities, it appeared that compounds in which the upper unit D was 
missing, were poor Chk1 inhibitors suggesting that this ring is required for Chk1 inhibition. In 
contrast, the lower heterocyclic unit E is not absolutely required for Chk1 inhibition. Moreover, it 
seems that substitution of the imide nitrogen with a hydroxymethyl group was not detrimental to Chk1 
inhibitory activity. 
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6. Conclusions 
 
Most of the granulatimide derivatives clearly represent a promising class of antitumor agents due to 
their potent inhibitory activity against different kinases. Recent reports on indolocarbazole analogues 
have shown that minimal structural modifications are able to modify both the biological targets and 
induce selectivity towards tumor cell lines. For instance, substitutions in 3,9-positions of the 
rebeccamycin framework may induce strong inhibitory properties toward various kinases and 
selectivity toward the tumor cell lines. The same observation is also valuable in the case of 
pyrrolocarbazole analogues which means that it could be of interest in these carbazole series to 
evaluate systematically the different compounds toward a large panel of kinases, such a profile of 
kinase selectivity being obtainable thanks to modern high-throughput technologies [80,81].  
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